AcuamarkDX

Detecting Cancer At Its Earliest Stages

About this Event

The earlier cancer is detected the more likely it is to be curable. For example, when colorectal cancer is detected in stage 3 or later, the survival rate is less than 50%. The survival rate climbs to more than 90% if it is detected in stage 1.

AcuamarkDX (ADX) has developed a blood-based cancer detection platform for all stage 1 and 2 cancers. It is accurate, scalable, has a clear adoption path, and offers the potential for high margins. ADX can own this extremely valuable “early detection space” because the test is different from current cancer tests in four critical ways:
  • It is based on an optimized Quantitative PCR, currently the gold standard in infectious disease diagnostics, and unlocked for early blood-based cancer detection.
  • Uses an AI-enhanced, novel platform for ultra-sensitive cancer detection.
  • Features high-throughput, scalable technology that seamlessly integrates into existing clinical workflows.
  • Enables cost-effective, first-line population-wide cancer screening with >70% margins anticipated.

Because AcuamarkDX is a blood test, it is easily integrated into an annual physical exam by simply adding a vial. Currently, more than 50% of patients do not get screened for the current markers recommended by the FDA. Furthermore, tests like Cologuard™ stool samples are not accurate enough, provide false positives and are an unpleasant experience.

ADX has tested more than 300 patients. They expect to use new funds to test 3,000 more. They also intend to begin an FDA pivotal study for colorectal cancer and commercialization so that LDT lab testing can begin to generate revenue as early as late next year.

Register today to watch this online event with AcuamarkDX co-founder and CEO, Bernard Peperstraete, MD. The market for CRC testing alone is $23B in the US and $100B globally. When expanded to other solid tumor cancers, the TAM could easily double.

Video On Demand

– Recorded

May 13

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.